BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19381822)

  • 1. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
    Han ES; Lin P; Wakabayashi M
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
    Gui T; Shen K
    Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of antiangiogenesis therapy: bevacizumab and beyond.
    Cortés-Funes H
    Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with bevacizumab in the management of epithelial ovarian cancer.
    Burger RA
    J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
    Han ES; Wakabayashi M; Leong L
    Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A; Kendrick JE; Finkler NJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
    Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
    Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational agents in the management of non-small cell lung cancer.
    Pennell NA; Mekhail T
    Curr Oncol Rep; 2009 Jul; 11(4):275-84. PubMed ID: 19508832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
    Prescrire Int; 2013 Mar; 22(136):64-7. PubMed ID: 23593688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted therapies. New hopes, new challenges].
    Barlési F
    Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent development of molecular-targeted drugs in lung cancer.
    Saijo N; Kenmotsu H
    Intern Med; 2010; 49(18):1923-34. PubMed ID: 20847494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic agents in ovarian cancer.
    Collinson F; Jayson G
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):44-53. PubMed ID: 19125003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.